title: The statement of the Polish Society of Allergology experts on the treatment of difficult-to-treat asthma.
abstract: The main objective of asthma treatment is to control symptoms of the disease; however, despite the availability of guidelines and many groups of medications, the degree of control of this condition is insufficient. In difficult-to-treat asthma, the optimal control cannot be achieved due to reasons independent of the disease. Factors worsening asthma control include: inadequate treatment plan (low therapy adherence and compliance), inappropriate inhalation technique, insufficient symptom control using the available classes of medications, incomplete response to treatment (non-responders, steroid-resistance), incorrect diagnosis of asthma or comorbidities, and environmental factors. In order to achieve the optimal asthma control, it is recommended to: take therapeutic decisions with the patient, assess the probability of non-compliance, perform detailed diagnostics and initiate treatment of concomitant diseases, carry out differential diagnosis of conditions mimicking asthma, educate the patient as to the inhalation technique and check it, eliminate unfavourable environmental factors, and modify current treatment. New treatment options for patients with asthma include: ultra-long-acting beta2-agonists, long-acting muscarine receptor antagonists (LAMA), monoclonal antibodies, and non-pharmacological interventions. The only LAMA approved for treatment of asthma is tiotropium bromide. The analyses performed demonstrated a high efficacy of tiotropium in terms of improved lung function parameters and prolonged time to the first asthma exacerbation. It is recommended as an add-on therapy at asthma treatment steps 4 and 5 according to GINA (Global Initiative for Asthma) 2014. The optimal asthma control is important from the medical as well as the economical point of view.
authors.forename: Anna
authors.initials: A
authors.lastname: Bodzenta-Łukaszyk
authors.forename: Andrzej M
authors.initials: AM
authors.lastname: Fal
authors.forename: Ewa
authors.initials: E
authors.lastname: Jassem
authors.forename: Marek L
authors.initials: ML
authors.lastname: Kowalski
authors.forename: Piotr
authors.initials: P
authors.lastname: Kuna
authors.affiliation: Division of Internal Medicine Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. maciej.kupczyk@umed.pl.
authors.forename: Maciej
authors.initials: M
authors.lastname: Kupczyk
mesh_terms: D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D017048:Health Care Costs; D006801:Humans; D010349:Patient Compliance; D011044:Poland; D000069447:Tiotropium Bromide / Q000008:administration & dosage
chemical_list: D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D000069447:Tiotropium Bromide